These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17389294)

  • 1. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Arch Intern Med; 2007 Mar; 167(6):612-3. PubMed ID: 17389294
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer.
    Alibhai SM; Breunis H; Timilshina N; Marzouk S; Stewart D; Tannock I; Naglie G; Tomlinson G; Fleshner N; Krahn M; Warde P; Canning SD
    J Clin Oncol; 2010 Dec; 28(34):5030-7. PubMed ID: 21041708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy.
    Hamilton EJ; Gianatti E; Strauss BJ; Wentworth J; Lim-Joon D; Bolton D; Zajac JD; Grossmann M
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):377-83. PubMed ID: 21118287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
    BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer.
    Dale W
    J Clin Oncol; 2009 Jul; 27(21):3420-2. PubMed ID: 19506150
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estradiol and cognition during androgen deprivation in men with prostate carcinoma.
    Wassersug RJ; Wadhwa D
    Cancer; 2005 Nov; 104(9):2032-3; author reply 2033. PubMed ID: 16196043
    [No Abstract]   [Full Text] [Related]  

  • 15. Body image perceptions in men with prostate cancer.
    Harrington JM; Jones EG; Badger T
    Oncol Nurs Forum; 2009 Mar; 36(2):167-72. PubMed ID: 19273405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
    Galvão DA; Taaffe DR; Spry N; Newton RU
    Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?
    Wadhwa VK; Parr NJ
    Urology; 2009 Jun; 73(6):1347-51. PubMed ID: 19362345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.